#METABOLOMICS WORKBENCH hjyoo2_20200818_181947 DATATRACK_ID:2131 STUDY_ID:ST001467 ANALYSIS_ID:AN002442 PROJECT_ID:PR000999
VERSION             	1
CREATED_ON             	August 27, 2020, 10:02 am
#PROJECT
PR:PROJECT_TITLE                 	Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation
PR:PROJECT_TITLE                 	study
PR:PROJECT_SUMMARY               	A multimodal approach was performed to investigate the effects of BST204 on the
PR:PROJECT_SUMMARY               	alleviation of chemotherapy-induced cachexia. The targeted metabolome changed
PR:PROJECT_SUMMARY               	with chemotheraphy-induced cachexia and the changes were reversed with potential
PR:PROJECT_SUMMARY               	treatment of the cachexia.
PR:INSTITUTE                     	Asan medical Center, University of Ulsan College of Medicine
PR:LAST_NAME                     	Yoo
PR:FIRST_NAME                    	Hyun Ju
PR:ADDRESS                       	88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea
PR:EMAIL                         	yoohyunju@amc.seoul.kr
PR:PHONE                         	82-02-3010-4029
#STUDY
ST:STUDY_TITLE                   	Metabolites changes related to glucose-mediated energy production in
ST:STUDY_TITLE                   	chemotheraphy-induced cachexia
ST:STUDY_SUMMARY                 	Targeted metabolomics platforms included amino acids and metabolites related to
ST:STUDY_SUMMARY                 	glucose-mediated energy production. The targeted metabolome changed with
ST:STUDY_SUMMARY                 	chemotheraphy-induced cachexia, and the changes were reversed with potential
ST:STUDY_SUMMARY                 	treatment of the cachexia. .rdb files were included as raw data files where
ST:STUDY_SUMMARY                 	detailed information regarding MRM transitions and internal standards can be
ST:STUDY_SUMMARY                 	found. Several amino acids (Gly, Pro, Gln, Taurine) were analyzed after dilution
ST:STUDY_SUMMARY                 	because their peak intensities were too high. Thus their analysis was performed
ST:STUDY_SUMMARY                 	separately from other amino acids, and their rdb files were saved in separate
ST:STUDY_SUMMARY                 	rdb files.
ST:INSTITUTE                     	Asan medical Center, University of Ulsan College of Medicine
ST:LAST_NAME                     	Yoo
ST:FIRST_NAME                    	Hyun Ju
ST:ADDRESS                       	88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea
ST:EMAIL                         	yoohyunju@amc.seoul.kr
ST:PHONE                         	82-02-3010-4029
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1p	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2p	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3p	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4p	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5p	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6p	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1m	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2m	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3m	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4m	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5m	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6m	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1p_2	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2p_2	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3p_2	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4p_2	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5p_2	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6p_2	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1m_2	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2m_2	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3m_2	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4m_2	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5m_2	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6m_2	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1m_1	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2m_1	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3m_1	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4m_1	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5m_1	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6m_1	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
#COLLECTION
CO:COLLECTION_SUMMARY            	Mice were randomized into five groups (n = 10 each): untreated,
CO:COLLECTION_SUMMARY            	non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group);
CO:COLLECTION_SUMMARY            	tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving
CO:COLLECTION_SUMMARY            	5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving
CO:COLLECTION_SUMMARY            	5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells
CO:COLLECTION_SUMMARY            	(1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of
CO:COLLECTION_SUMMARY            	phosphate-buffered saline were subcutaneously implanted in the right flank of
CO:COLLECTION_SUMMARY            	8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached
CO:COLLECTION_SUMMARY            	100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was
CO:COLLECTION_SUMMARY            	assigned and drug administration started for 5-FU and BST204 groups. BST204
CO:COLLECTION_SUMMARY            	(batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South
CO:COLLECTION_SUMMARY            	Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50
CO:COLLECTION_SUMMARY            	mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2;
CO:COLLECTION_SUMMARY            	2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable.
CO:COLLECTION_SUMMARY            	BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle:
CO:COLLECTION_SUMMARY            	days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according
CO:COLLECTION_SUMMARY            	to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our
CO:COLLECTION_SUMMARY            	study was determined according to IACUC guidelines, which recommend euthanasia
CO:COLLECTION_SUMMARY            	with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our
CO:COLLECTION_SUMMARY            	study period was limited to day 11. At this point, the change in tumor volumes
CO:COLLECTION_SUMMARY            	was up to 810%, and significant cachexia was observed.
CO:SAMPLE_TYPE                   	Blood (plasma)
CO:COLLECTION_LOCATION           	muscle
CO:STORAGE_CONDITIONS            	-20℃
#TREATMENT
TR:TREATMENT_SUMMARY             	Mice were randomized into five groups (n = 10 each): untreated,
TR:TREATMENT_SUMMARY             	non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group);
TR:TREATMENT_SUMMARY             	tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving
TR:TREATMENT_SUMMARY             	5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving
TR:TREATMENT_SUMMARY             	5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells
TR:TREATMENT_SUMMARY             	(1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of
TR:TREATMENT_SUMMARY             	phosphate-buffered saline were subcutaneously implanted in the right flank of
TR:TREATMENT_SUMMARY             	8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached
TR:TREATMENT_SUMMARY             	100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was
TR:TREATMENT_SUMMARY             	assigned and drug administration started for 5-FU and BST204 groups. BST204
TR:TREATMENT_SUMMARY             	(batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South
TR:TREATMENT_SUMMARY             	Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50
TR:TREATMENT_SUMMARY             	mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2;
TR:TREATMENT_SUMMARY             	2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable.
TR:TREATMENT_SUMMARY             	BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle:
TR:TREATMENT_SUMMARY             	days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according
TR:TREATMENT_SUMMARY             	to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our
TR:TREATMENT_SUMMARY             	study was determined according to IACUC guidelines, which recommend euthanasia
TR:TREATMENT_SUMMARY             	with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our
TR:TREATMENT_SUMMARY             	study period was limited to day 11. At this point, the change in tumor volumes
TR:TREATMENT_SUMMARY             	was up to 810%, and significant cachexia was observed.
TR:TREATMENT                     	5-FU was injected intraperitoneally in 3-day cycles. BST204 was orally
TR:TREATMENT                     	administerd in 5-day cycles.
TR:TREATMENT_DOSE                	5-FU (50 mg/kg), BST204 (100 or 200 mg/kg)
TR:ANIMAL_ENDP_EUTHANASIA        	study period was limited by day 11
TR:TREATMENT_COMPOUND            	5-FU, BST204
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Metabolites related to glucose-mediated energy metabolism were extracted using
SP:SAMPLEPREP_SUMMARY            	LLE. Amino acids and bioamines were also extracted using LLE and underwent
SP:SAMPLEPREP_SUMMARY            	chemical derivatization with phenylisothiocyante.
SP:PROCESSING_STORAGE_CONDITIONS 	4℃
SP:EXTRACTION_METHOD             	Liquid Liquid Extraction (LLE)
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Metabolites related to glucose-mediated metabolites were analyzed with LC-MS/MS
CH:CHROMATOGRAPHY_SUMMARY        	(MRM)
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Agilent 1290
CH:COLUMN_NAME                   	Synergi fusion RP (50 x 2 mm)
CH:FLOW_GRADIENT                 	0% B for 5 min, 0% to 90% B for 2 min, hold at 90% B for 8 min, 90% to 0% B for
CH:FLOW_GRADIENT                 	1 min, and then hold at 0% B for 9 min
CH:FLOW_RATE                     	70 μL/min except for minutes 7 to 15, when it was 140 µL/min
CH:COLUMN_TEMPERATURE            	23
CH:SOLVENT_A                     	5 mM ammonium acetate in H2O
CH:SOLVENT_B                     	5 mM ammonium acetate in ACN
CH:INTERNAL_STANDARD             	13C5-glutamine
CH:SAMPLE_INJECTION              	3 uL
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
AN:ACQUISITION_DATE              	2018 May
#MS
MS:INSTRUMENT_NAME               	ABI Sciex 5500 QTrap
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	NEGATIVE
MS:MS_COMMENTS                   	Metabolites related to glucose-mediated energy production MRM mode Analyst 1.52
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	area ratio
MS_METABOLITE_DATA_START
Samples	NTB_1p_2	NTB_2p_2	NTB_3p_2	NTB_4p_2	NTB_5p_2	NTB_6p_2	TB_1p_2	TB_2p_2	TB_3p_2	TB_4p_2	TB_5p_2	TB_6p_2	5FU_1p_2	5FU_2p_2	5FU_3p_2	5FU_4p_2	5FU_5p_2	5FU_6p_2	BST100_1p_2	BST100_2p_2	BST100_3p_2	BST100_4p_2	BST100_5p_2	BST100_6p_2	BST200_1p_2	BST200_2p_2	BST200_3p_2	BST200_4p_2	BST200_5p_2	BST200_6p_2	NTB_1m_2	NTB_2m_2	NTB_3m_2	NTB_4m_2	NTB_5m_2	NTB_6m_2	TB_1m_2	TB_2m_2	TB_3m_2	TB_4m_2	TB_5m_2	TB_6m_2	5FU_1m_2	5FU_2m_2	5FU_3m_2	5FU_4m_2	5FU_5m_2	5FU_6m_2	BST100_1m_2	BST100_2m_2	BST100_3m_2	BST100_4m_2	BST100_5m_2	BST100_6m_2	BST200_1m_2	BST200_2m_2	BST200_3m_2	BST200_4m_2	BST200_5m_2	BST200_6m_2
Factors	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:5FU | Sample Source:plasma	Group:batch1 | Treatment:5FU | Sample Source:plasma	Group:batch1 | Treatment:5FU | Sample Source:plasma	Group:batch2 | Treatment:5FU | Sample Source:plasma	Group:batch2 | Treatment:5FU | Sample Source:plasma	Group:batch2 | Treatment:5FU | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:5FU | Sample Source:muscle	Group:batch1 | Treatment:5FU | Sample Source:muscle	Group:batch1 | Treatment:5FU | Sample Source:muscle	Group:batch2 | Treatment:5FU | Sample Source:muscle	Group:batch2 | Treatment:5FU | Sample Source:muscle	Group:batch2 | Treatment:5FU | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle
D-Glucose	658.263	619.76	489.655	745.636	779.412	607.375	541.667	536.058	514.706	642.254	444.751	451.902	352.941	318.501	205.425	322.296	475.309	349.593	594.972	515.228	500	541.985	662.162	745.798	368.7	591.011	588.372	401.515	622.449	442.553	138.42	199.24	74.18	105.92	105.86	93.8	89.49	88.49	85.2	92.05	95.64	114.55	31.81	65.74	54.28	65.89	85.65	62.74	106.24	103.33	96.06	91.81	96.27	103.2	96.61	162.52	85.95	117.17	90.64	139.56
Glucose 6-phosphate	1.958	2.417	1.79	2.166	1.643	1.61	2.094	1.976	1.968	1.997	2.64	1.921	0.81	1.171	0.953	0.889	1.091	1.014	1.581	1.456	1.272	1.829	0.995	1.758	1.197	1.555	1.542	1.22	1.634	1.669	142.16	2.85	1.51	1.81	2.49	29.15	59.08	29.67	47.71	15.83	4.24	14.9	0.89	2.28	0.47	1.19	3.03	6.94	15.81	19.12	1.99	1.07	13.37	1.02	8.73	20	5.71	13.41	5.16	18.67
Fructose 1,6-bisphosphate	0.265	0.236	0.228	0.152	0.193	0.191	0.511	0.412	0.33	0.513	0.525	0.362	0.24	0.131	0.129	0.137	0.142	0.148	0.492	0.273	0.194	0.239	0.171	0.239	0.185	0.336	0.204	0.165	0.247	0.185	40.65	0.74	0.8	1.11	1.75	11.83	16.89	12.16	14.99	6.01	2.27	7.31	0.28	0.62	0.15	0.51	1.05	2.04	5.35	7.56	1.03	0.42	4.3	0.51	2.22	8.2	1.77	5.89	1.26	8.73
3-Phosphoglyceric acid	0.866	1.053	0.781	0.576	0.509	0.684	1.094	1.096	0.887	0.961	1.105	0.899	0.723	0.403	0.62	0.499	0.535	0.604	0.591	0.557	0.382	0.491	0.503	0.54	0.639	0.701	0.658	0.693	0.597	0.723	10.85	1.03	0.7	0.77	1.44	3.67	5.76	4.43	3.74	1.19	2.7	2.93	0.36	0.19	0.52	1.01	0.63	0.48	1.98	2.38	0.68	0.44	1.22	0.77	1.97	3.67	1.18	2.72	0.62	2.21
Phosphoenolpyruvic acid	0.412	0.429	0.317	0.316	0.344	0.48	0.47	0.444	0.445	0.499	0.396	0.372	0.285	0.21	0.236	0.241	0.237	0.232	0.254	0.239	0.211	0.313	0.176	0.169	0.305	0.371	0.237	0.278	0.313	0.311	1.48	0.16	0.12	0.13	0.16	0.64	1	1.01	0.87	0.32	0.48	0.71	0.05	0.04	0.12	0.12	0.13	0.1	0.58	0.6	0.1	0.08	0.17	0.13	1.49	0.34	0.35	1.04	0.13	0.59
Pyruvic acid	85.97	107.485	61.724	93.267	79.902	60.954	75.49	69.328	68.169	73.481	77.405	74.538	56.704	79.391	81.368	47.461	54.527	46.748	95.178	64.407	34.86	54.73	61.556	69.958	85.676	82.938	77.528	74.811	58.511	65.619	29.68	36.65	24.59	30.69	27.99	25.54	18.67	17.18	16.49	27.25	27.07	27.62	9.39	15.32	12.69	21.73	26.84	18.67	20.51	17.82	27.22	27.12	19.69	27.22	17.31	30.21	33.2	27.42	18.67	34.93
L-Lactic acid	901.493	769.461	503.448	947.631	740.196	622.56	818.627	733.193	664.789	781.768	774.049	792.608	650.838	829.04	846.698	485.651	567.901	573.171	939.086	588.983	353.69	542.793	672.769	829.832	832.891	755.924	822.472	839.015	610.638	700.555	347.92	403.23	219.78	285.05	261.02	245.31	202.04	204.74	194.17	260.68	249.87	265.65	114.07	163.11	152.07	213.76	262.66	197.89	242.96	209.25	194.66	229.2	196.28	238.65	208.64	350.04	313.3	250.94	198.24	320
Citric acid	1029.851	1355.742	1314.371	1186.207	1384.804	1210.412	965.686	1076.923	1002.101	1445.07	1217.002	1177.528	111.732	224.041	176.581	133.726	213.992	211.382	697.97	521.186	671.756	779.279	356.979	686.975	587.678	613.483	484.848	577.551	374.468	325.323	6.41	10.35	23.42	3.75	4.56	3.2	5.33	4.27	4.67	3.48	3.59	3.86	5.8	3.96	6.76	3.79	3.31	3.73	4.71	5.21	4.93	5.46	4.06	3.83	4.97	4.84	5.04	2.67	3.16	3.22
Succinic acid	9.194	13.529	7.216	10.207	9.177	17.223	6.25	5.666	5.048	4.648	10.649	11.725	1.33	1.756	1.927	1.932	1.961	1.803	4.188	4.513	3.537	2.635	2.025	10.126	4.377	6.303	4.18	8.884	5.777	4.857	19.83	11.85	9.96	4.74	7.32	8.3	6.93	4.67	5.23	5.04	5.42	5.41	0.88	2.78	2.1	2.62	2.83	3.31	6.55	5.57	3.52	3.19	2.78	6.58	3.86	5.89	3.75	5.03	3.34	3.39
Fumaric acid	8.269	6.228	9.241	10.2	10.417	9.219	2.194	3.185	1.952	2.101	2.499	3.624	0.439	0.985	0.806	0.476	1.163	0.508	2.538	2.225	1.056	1.574	1.103	3.466	1.419	1.912	3.093	1.197	1.227	1.734	6.48	5.53	4.33	1.57	1.89	2.39	3.13	2.08	3.09	1.91	1.87	2.05	2.43	2.06	1.4	1.83	2.33	1.29	2.4	3.01	2.29	1.71	2.01	1.76	2.99	4.17	2	1.99	1.6	1.99
Malic acid	65.075	101.401	80.69	91.022	98.529	77.44	23.167	24.517	19.303	18.466	28.732	36.465	13.402	10.703	10.212	14.923	9.444	16.301	16.345	10.657	16.972	15	11.487	30.252	12.361	12.938	15.213	28.14	15.928	14.34	50.63	41.63	31.18	10.28	12.91	15.44	24.12	15.6	24.2	12.96	12.32	12.44	16.56	14.95	10.12	11.08	14.36	8.63	18.02	22.46	14.32	11.1	12.78	10.51	23.35	32.61	15.67	13.5	9.73	12.62
Adenosine monophosphate	0.151	0.386	0.171	0.11	0.098	0.125	0.101	0.112	0.06	0.096	0.058	0.062	0.098	0.225	0.255	0.074	0.088	0.19	0.102	0.046	0.106	0.136	0.049	0.165	0.148	0.052	0.073	0.175	0.082	0.079	0.36	0.67	0.47	0.64	0.7	0.29	0.18	0.2	0.14	0.28	0.22	0.3	0.21	0.34	0.39	0.44	0.3	0.41	0.2	0.16	0.15	0.39	0.27	0.34	0.3	0.2	0.15	0.21	0.31	0.25
Adenosine triphosphate	0.095	0.088	0.13	0.121	0.115	0.103	0.071	0.068	0.052	0.047	0.063	0.052	0.043	0.024	0.043	0.032	0.021	0.025	0.068	0.052	0.03	0.052	0.026	0.006	0.037	0.042	0.044	0.019	0.027	0.008	1.23	0.45	0.2	0.28	0.36	0.83	0.94	0.98	0.93	0.45	0.76	0.65	0.05	0.1	0.32	0.28	0.25	0.31	0.82	0.61	0.65	0.38	0.35	0.26	0.45	0.9	0.4	0.58	0.22	0.58
6-Phosphogluconic acid	6.358	6.228	5.414	5.636	6.52	5.401	9.167	8.113	10.337	7.143	9.69	8.031	2.464	3.279	2.524	3.819	3.272	3.557	10.584	6.462	6.31	6.622	2.952	5.588	4.987	7.275	7.279	5.152	6.184	5.489	0.47	0.38	0.17	0.16	0.19	0.24	0.37	0.29	0.35	0.21	0.19	0.25	0.11	0.1	0.12	0.1	0.09	0.11	0.27	0.26	0.18	0.11	0.15	0.17	0.38	0.19	0.23	0.2	0.09	0.24
D-Ribose 5-phosphate	0.722	0.707	0.759	0.621	0.608	0.809	1.006	1.027	1.101	0.95	1.02	0.988	0.598	0.492	0.46	0.486	0.447	0.459	0.688	0.492	0.468	0.532	0.453	0.637	0.552	0.717	0.635	0.634	0.524	0.675	2.26	2.06	1.39	1.27	1.25	1.2	1.57	1.81	1.23	1.23	1.19	1.37	2.44	1.72	1.9	1.45	1.15	1.54	1.15	1.3	1.79	1.46	1.19	1.57	2.15	2.53	1.65	1.49	1.24	1.92
Ribose 1,5-bisphosphate	0.213	0.216	0.234	0.187	0.168	0.236	0.2625	0.23284	0.22692	0.28169	0.26622	0.24045	0.17	0.176	0.179	0.141	0.158	0.121	0.274	0.236	0.142	0.238	0.222	0.275	0.201	0.216	0.172	0.176	0.204	0.19	0.03	0.03	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.01	0.01	0.03	0.01	0.02	0.01	0.01	0.01	0.02	0.02	0.01	0.01	0.01	0.01	0.02	0.03	0.02	0.01	0.01	0.01
D-Sedoheptulose 7-phosphate	0.57	0.63	0.634	0.693	0.843	0.792	1.008	0.9	1.385	1.394	1.199	1.375	0.374	0.396	0.274	0.422	0.313	0.435	0.768	0.914	0.498	0.598	0.773	0.297	0.467	0.521	0.688	0.626	0.673	0.723	0.4	0.11	0.09	0.04	0.06	0.14	0.22	0.15	0.19	0.07	0.11	0.11	0.08	0.08	0.05	0.1	0.05	0.07	0.11	0.13	0.05	0.04	0.1	0.05	0.13	0.23	0.1	0.14	0.07	0.13
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	KEGG ID	Pubchem ID
D-Glucose	C00031	5793
Glucose 6-phosphate	C00092	5958
Fructose 1,6-bisphosphate	C00354	445557
3-Phosphoglyceric acid	C00597	724
Phosphoenolpyruvic acid	C00074	1005
Pyruvic acid	C00022	1060
L-Lactic acid	C00256	61503
Citric acid	C00158	311
Succinic acid	C00042	1110
Fumaric acid	C00122	444972
Malic acid	C03668	525
Adenosine monophosphate	C00020	6083
Adenosine triphosphate	C00002	5957
6-Phosphogluconic acid	C00345	91493
D-Ribose 5-phosphate	C00117	439167
Ribose 1,5-bisphosphate	C01151	14035695
D-Sedoheptulose 7-phosphate	C00281	22833559
METABOLITES_END
#END